PL4284511T3 - Azachinoliny jako inhibitory cd38 - Google Patents

Azachinoliny jako inhibitory cd38

Info

Publication number
PL4284511T3
PL4284511T3 PL22704226.4T PL22704226T PL4284511T3 PL 4284511 T3 PL4284511 T3 PL 4284511T3 PL 22704226 T PL22704226 T PL 22704226T PL 4284511 T3 PL4284511 T3 PL 4284511T3
Authority
PL
Poland
Prior art keywords
azaquinolines
inhibitors
Prior art date
Application number
PL22704226.4T
Other languages
English (en)
Inventor
Jennifer DOWNING
Kevin Wayne Kuntz
Laurie B. Schenkel
Melissa Marie Vasbinder
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of PL4284511T3 publication Critical patent/PL4284511T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL22704226.4T 2021-01-29 2022-01-28 Azachinoliny jako inhibitory cd38 PL4284511T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163143245P 2021-01-29 2021-01-29
PCT/US2022/014221 WO2022165114A1 (en) 2021-01-29 2022-01-28 Quinolines and azaquinolines as inhibitors of cd38

Publications (1)

Publication Number Publication Date
PL4284511T3 true PL4284511T3 (pl) 2025-12-22

Family

ID=80446310

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22704226.4T PL4284511T3 (pl) 2021-01-29 2022-01-28 Azachinoliny jako inhibitory cd38

Country Status (25)

Country Link
US (2) US11952377B2 (pl)
EP (2) EP4674415A3 (pl)
JP (2) JP7777596B2 (pl)
KR (1) KR20230141799A (pl)
CN (1) CN117580829A (pl)
AR (1) AR124718A1 (pl)
AU (1) AU2022212035A1 (pl)
BR (1) BR112023014898A2 (pl)
CA (1) CA3208851A1 (pl)
CL (2) CL2023002163A1 (pl)
CO (1) CO2023009803A2 (pl)
CR (1) CR20230323A (pl)
DO (1) DOP2023000142A (pl)
EC (1) ECSP23056223A (pl)
ES (1) ES3042412T3 (pl)
HR (1) HRP20251111T1 (pl)
HU (1) HUE072981T2 (pl)
IL (1) IL304466A (pl)
JO (1) JOP20230160A1 (pl)
MX (1) MX2023008701A (pl)
PE (1) PE20232047A1 (pl)
PL (1) PL4284511T3 (pl)
RS (1) RS67253B1 (pl)
TW (1) TW202241418A (pl)
WO (1) WO2022165114A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
WO2024217995A1 (en) 2023-04-20 2024-10-24 Syngenta Crop Protection Ag Pesticidally active dihydropyridinone derivatives
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765792B2 (en) 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
CA2854447A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
WO2014159837A1 (en) * 2013-03-14 2014-10-02 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
CA2969178A1 (en) 2014-12-03 2016-06-09 Glaxosmithkline Intellectual Property (No.2) Limited Cd38 inhibitors and methods of treatment
US11059817B2 (en) 2015-09-23 2021-07-13 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
WO2021087087A1 (en) 2019-10-30 2021-05-06 Mitobridge Inc. N-cyclohexyl-5-(thiazol-5-yl)-1h-indole-7-carboxamide derivatives and related compounds as cd38 inhibitors for increasing nad+ and for the treatment of e.g. muscular disorders
AR121759A1 (es) 2020-04-07 2022-07-06 Mitobridge Inc Inhibidores de cd38

Also Published As

Publication number Publication date
US20220242862A1 (en) 2022-08-04
MX2023008701A (es) 2023-11-29
HUE072981T2 (hu) 2025-12-28
CN117580829A (zh) 2024-02-20
US11952377B2 (en) 2024-04-09
JP2024506814A (ja) 2024-02-15
KR20230141799A (ko) 2023-10-10
DOP2023000142A (es) 2023-08-31
EP4284511B1 (en) 2025-07-16
US20240279224A1 (en) 2024-08-22
CL2023002163A1 (es) 2024-01-05
JP7777596B2 (ja) 2025-11-28
AU2022212035A9 (en) 2025-03-06
BR112023014898A2 (pt) 2023-10-31
EP4284511C0 (en) 2025-07-16
CL2024001535A1 (es) 2024-11-04
JP2025160175A (ja) 2025-10-22
ES3042412T3 (en) 2025-11-20
ECSP23056223A (es) 2023-11-30
AR124718A1 (es) 2023-04-26
CA3208851A1 (en) 2022-08-04
AU2022212035A1 (en) 2023-08-03
EP4284511A1 (en) 2023-12-06
HRP20251111T1 (hr) 2025-11-21
WO2022165114A1 (en) 2022-08-04
EP4674415A3 (en) 2026-03-04
JOP20230160A1 (ar) 2023-07-20
IL304466A (en) 2023-09-01
TW202241418A (zh) 2022-11-01
EP4674415A2 (en) 2026-01-07
RS67253B1 (sr) 2025-10-31
CO2023009803A2 (es) 2023-10-09
PE20232047A1 (es) 2023-12-27
CR20230323A (es) 2023-10-02

Similar Documents

Publication Publication Date Title
IL289878A (en) Tricyclic amides as inhibitors of cd38
HUE072981T2 (hu) Azakinolinok mint CD38 gátlók
IL320739A (en) rock2 inhibitors
IL317736A (en) Compounds as AXL inhibitors
IL308476A (en) Inhibitors of the menin-mil interaction
ZA202106766B (en) Compounds as inhibitors of macrophage migration inhibitory factor
IL313548A (en) MET kinase inhibitors
IL304159A (en) A preparation containing bl-8040
IL316616A (en) ROCK2 inhibitors
GB202103774D0 (en) Detectiion of Ransomware
PL4192814T3 (pl) Inhibitory transglutaminaz
GB202411655D0 (en) Application of circHIF1a
SI4192813T1 (sl) Zaviralci transglutaminaz
IL288782B1 (en) Sustained-release alpha-ketoglutarate preparations
SI4192812T1 (sl) Zaviralci transglutaminaz
EP4405346A4 (en) SMALL MOLECULE INHIBITORS OF TEAD-YAP
IL317047A (en) Solid forms of heterocyclylamides as IRAK4 inhibitors
IL291368A (en) Inhibits expression of methadherin
ES3065110T3 (en) Novel inhibitors of autotaxin
GB202107612D0 (en) Inhibitors of metallo-beta-lactamases
HK40075513A (en) Heterobicyclic amides as inhibitors of cd38
GB202203181D0 (en) Inhibitors of elF4A
PT4192814T (pt) Inibidores de transglutaminases
GB202114327D0 (en) Uses of terpenophenolic compounds
HK40109568A (en) Compounds and their uses as cd38 inhibitors